Unraveling mysteries in multiple myeloma
Access the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information (PI) for daratumumab. Adverse event reporting information can be found at the bottom of the page.
- Adding anti-CD38 mAbs to standard-of-care regimens in transplant-eligible NDMM
- Case study: Considering treatment options in transplant-eligible NDMM
- Case study: Adapting to fitness and frailty in transplant-ineligible NDMM
- Panel Q&A
- EHA 2025 poster: Phase 3 CEPHEUS trial cytogenetic subgroup analysis
What needs to be considered when selecting treatment regimens in patients with newly diagnosed multiple myeloma (NDMM)? Hear expert perspectives in symposium highlight clips from the 2024 European Hematology Association (EHA) Congress in Madrid, Spain. María-Victoria Mateos (University of Salamanca, Spain) chairs the discussion with Roberto Mina (University of Torino, Italy), Yael Cohen (Tel Aviv Sourasky Medical Center, Israel), and Salomon Manier (University of Lille, France).
What is the impact of incorporating CD38 mAbs in patients with transplant-eligible NDMM? Roberto Mina reviews key data from several phase 3 studies exploring the impact of CD38 mAbs in induction, consolidation, and maintenance in ASCT-eligible patients. View transcript.
“We need to apply our clinical judgement and experience and consider the unique features of the patient.” Through a case study–led discussion, Yael Cohen discusses treatment considerations and personalization for a 69-year-old patient with high-risk NDMM. View transcript.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed semper dapibus sapien. Etiam tempus est ut dui hendrerit, sed lacinia nibh volutpat. Suspendisse aliquam ipsum arcu, eu efficitur libero mollis eget. View transcript.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed semper dapibus sapien. Etiam tempus est ut dui hendrerit, sed lacinia nibh volutpat. Suspendisse aliquam ipsum arcu, eu efficitur libero mollis eget. View transcript.
CEPHEUS: Cytogenetic subgroup analysis
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) vs Rd in Transplant-Ineligible/Transplant-Deferred Newly Diagnosed Multiple Myeloma: Phase 3 CEPHEUS Trial Cytogenetic Subgroup Analysis
Study objectives: To report on outcomes in cytogenetic risk subgroups in CEPHEUS.
Meet the experts
María-Victoria Mateos, MD, PhD
María-Victoria Mateos is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. Her areas of interest include MM, the biology of plasma cells, and new drug development.
Disclosures: [Disclosures included here].
Roberto Mina, MD
Roberto Mina is an Assistant Professor at the University of Turin, Italy. Mina’s research focuses on plasma cell disorders, particularly MM, including diagnosis, measurable residual disease (MRD) assessment, and the treatment of older patients. His work includes the design and implementation of national and international clinical trials, especially in early-phase studies, exploring novel agents, transplant strategies, and advanced therapeutic sequencing.
Disclosures: [Disclosures included here].
Yael Cohen, MD
Yael Cohen is a senior physician at the Tel-Aviv Sourasky Medical Center, Israel. Research interests include clinical and translational research in MM.
Disclosures: [Disclosures included here].
Salomon Manier, MD, PhD
Salomon Manier is an Associate Professor of Hematology at Lille University Hospital, France. His interests include translational research in multiple myeloma.
Disclosures: [Disclosures included here].
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Johnson & Johnson. Please refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country for further information.
This content has been sponsored by Johnson & Johnson. The content hosted on this platform is intended for educational purposes. Any data about non- Johnson & Johnson products are based on publicly available information. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This educational activity is intended for healthcare professionals only.
JOB CODE, DATE OF PREPARATION
of interest
are looking at
saved
next event